Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

ATG-037selinexorPositive

AI Analysis

Summary

Antengene published preclinical research demonstrating the combination of CD73 small molecule inhibitor ATG-037 with selinexor in cancer gene therapy applications.

Outcome Details

preclinical research paper published on CD73 small molecule inhibitor ATG-037 combined with selinexor

Importance:2/10

Sentiment:

0.30

preclinicalresearch publicationcombination therapyCD73 inhibitorcancer gene therapy

Related Companies

$INTI $GBCYD $TRAX

Read the original article

Published by PR Newswire Biotech on September 14, 2026 4:26 AM

Read Original